Release details

2017-02-09 17:45 CET
  • Print
  • Share Share

Nicox to present at the 6th Annual LEERINK Partners Global Healthcare Conference

Nicox to present at the 6th Annual LEERINK Partners Global Healthcare Conference


February 9, 2017
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 6th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 16th, 2017 at 3:00 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.

A live webcast of the presentation will be available on the Company's website ( in "Presentations & Events". A replay of the webcast will be archived on the Nicox website for 90 days following the date of the presentation.

Michele Garufi will also be available for one-on-one meetings at the conference.
About Nicox
Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health.   By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma.  Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: .            
Analyst coverage
Bryan, Garnier & Co   Hugo Solvet                 Paris, France
Invest Securities          Martial Descoutures    Paris, France
Gilbert Dupont             Damien Choplain        Paris, France
Stifel                             Olivia Manser              London, UK
Upcoming financial and business conferences
March 6-8                      Cowen and Company 37th Annual Health Care Conference                 Boston, US
March 21-22                  Oppenheimer 27th Annual Healthcare Conference                        New York, US
April 4-5                         Needham's 16th Annual Healthcare Conference                             New York, US
May 3-4                         Deutsche Bank 42nd Annual Health Care Conference                            Boston, US   
May 30                          Gilbert Dupont 15th Annual Healthcare Conference                                Paris, France
June 19-22                    2017 BIO International Convention                                                         San Diego, US           
Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00

Investor Relations
Julien Perez, Valentine Brouchot
T +33 (0)1 44 71 94 94

Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746
United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
Nicolas Merigeau
T +33 (0)1 44 71 94 98
  United States
Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313,  Sophia Antipolis
06560 Valbonne,  France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99